Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report
| Autor: | Bingqing Hui, Lingyan Xu, Yanhong Gu, Xiaofeng Chen, Yuchen Yang, Yirui Zhou, Danping Wang, Xiaofei Li |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Myocarditis Pyridines Colorectal cancer Programmed Cell Death 1 Receptor Immunology chemistry.chemical_compound Internal medicine Regorafenib Antineoplastic Combined Chemotherapy Protocols medicine Humans Immunology and Allergy Neoplasm Metastasis Adverse effect Immune Checkpoint Inhibitors Myositis Aged Hepatitis business.industry Phenylurea Compounds Anti pd 1 medicine.disease digestive system diseases Myasthenia gravis Neoplasm Proteins chemistry Female Colorectal Neoplasms business |
| Zdroj: | Immunotherapy. 13:1317-1323 |
| ISSN: | 1750-7448 1750-743X |
| DOI: | 10.2217/imt-2020-0327 |
| Popis: | There exists a dilemma in the treatment of microsatellite stability (MSS) metastatic colorectal cancer (mCRC) owing to limited therapeutic options. Based on the promising results of the REGONIVO trial, combination of anti-PD-1 and regorafenib could be applicable for this kind of patients. Here we first report a case of an MSS mCRC patient who received sinitilimab plus regorafenib as third-line treatment and suffered severe multisystem treatment-related adverse events including Grade 3 myocarditis, myositis, myasthenia gravis, dermatitis, hepatitis, etc. Fortunately, all these adverse events were reversed with administration of corticosteroids. Though evidence of tumor shrinkage was not found, CEA levels markedly decreased. Therefore, anti-PD-1 plus regorafenib might be optional for the MSS mCRC patients which requires special caution in the clinical practice.Lay abstract There exists a dilemma in the treatment of metastatic colorectal cancer (mCRC) owing to limited therapeutic options. Based on the results of clinical trials, combination of anti-PD-1 and regorafenib is promising for these patients. Here we first report a case of an mCRC patient who received sinitilimab plus regorafenib as third-line treatment and suffered severe multisystem treatment-related adverse events including grade 3 myocarditis, myositis, myasthenia gravis, dermatitis, hepatitis, etc. Fortunately, all these adverse events were reversed with administration of corticosteroids. Though evidence of tumor shrinkage was not found, serum tumor marker level markedly decreased. Therefore, anti-PD-1 plus regorafenib might be optional for the mCRC patients which requires special caution in the clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|